ORGS 2.25 Stock Price Orgenesis Inc.
Range: | 0.87-10.8 | Vol Avg: | 34325 | Last Div: | 0 | Changes: | 0.11 |
Beta: | 1.32 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Tue Mar 13 2012 | Empoloyees: | 146 |
CUSIP: | 68619K204 | CIK: | 0001460602 | ISIN: | US68619K2042 | Country: | US |
CEO: | Ms. Vered Caplan M.Sc. | Website: | https://www.orgenesis.com |
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.